Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Endocardial Solutions

This article was originally published in The Gray Sheet

Executive Summary

Private placement of 1.1 mil. shares of common stock to institutional investors raises $10 mil. Proceeds will be used to help finance market introduction of the firm's $175,000 Ensite 3000 system, which was cleared by FDA for mapping of right atrial arrhythmias on April 21 and launched in early May (1"The Gray Sheet" April 26, p. 10). The firm has expanded its marketing force from ten to twenty reps since the launch and has a PMA pending at FDA for left atrial indications. Second-quarter financial results announced July 21 include revenues of $1.7 mil., compared to $435,406 for the second quarter of 1998. A net loss of $3.8 mil. compares to losses of $3.3 mil. for the comparable quarter last year

You may also be interested in...



Endocardial Solutions To Ship EnSite 3000 For Right Atrial Mapping In May

Shipments of Endocardial Solutions, Inc.' s EnSite 3000 system are anticipated to begin in early May following 510(k) clearance April 21 for use in diagnostic mapping of complex arrhythmias in the right atrium of the heart.

Aducanumab Review: Looking For Precedents – Long Ago And Far Afield

The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.

The Rebate Rule May Not Last, But It Changed The Pricing Debate

Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.

UsernamePublicRestriction

Register

OM004559

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel